EDAP TMS S.A. ( (EDAP) ) has released its Q4 earnings. Here is a breakdown of the information EDAP TMS S.A. presented to its investors.
EDAP TMS S.A. is a global leader in robotic energy-based therapies, specializing in minimally invasive medical devices using ultrasound technology, with a focus on prostate cancer treatment. The company recently reported record HIFU revenue for both the fourth quarter and full-year 2024, highlighting a 15.3% increase over the previous year. Key achievements include a 51% growth in U.S. Focal One HIFU procedures and the receipt of a CE Mark for treating deep infiltrating endometriosis. The publication of a landmark study in European Urology also demonstrated positive outcomes for Focal One HIFU in managing prostate cancer. Financially, EDAP TMS achieved a gross profit margin increase to 44.8% in Q4 2024, despite a net loss of EUR 1.9 million for the quarter. The company’s strategic focus remains on expanding its HIFU technology into new therapeutic areas while maintaining its leadership in prostate cancer treatment. Looking ahead, EDAP TMS aims to leverage its market-leading technology to create significant value for patients, physicians, and shareholders.